Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy

被引:52
|
作者
Fisher, Jonathan [1 ]
Anderson, John [1 ]
机构
[1] UCL, London, England
来源
FRONTIERS IN IMMUNOLOGY | 2018年 / 9卷
基金
英国惠康基金;
关键词
gamma delta; chimeric antigen receptor; adoptive transfer; alpha beta T cells; cancer immunotherapy; CHIMERIC-ANTIGEN-RECEPTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; MELANOMA-ASSOCIATED ANTIGEN; GENE-THERAPY; ANTITUMOR-ACTIVITY; NK CELLS; ADOPTIVE IMMUNOTHERAPY; NONPEPTIDE ANTIGENS; HUMAN NEUROBLASTOMA; PRESENTING CELLS;
D O I
10.3389/fimmu.2018.01409
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sharing both innate and adaptive immune properties,gamma delta T cells are attractive candidates for cellular engineering. As the cancer immunotherapy field becomes increasingly busy, orthogonal approaches are required to drive advancement. Engineering of alternative effector cell types such as gamma delta T cells represents one such approach. gamma delta T cells can be modified using many of the techniques used in alpha beta T cell engineering, with the added advantage of innate-like tumor recognition and killing. Progress has been made in T-cell receptor transfer to and from gamma delta T cells as well as in a number of chimeric antigen receptor-based strategies. As the cancer immunotherapy field moves beyond repetitive iteration of established constructs to more creative solutions, gamma delta T cells may offer an attractive chassis to drive anti-tumor responses that are not only broader, but also possess a more favorable safety profile.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Current Approaches to Engineering of NK Cells for Cancer Immunotherapy
    Streltsova, M. A.
    Barsov, E. V.
    Erokhina, S. A.
    Sapozhnikov, A. M.
    Kovalenko, E. I.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (24) : 2810 - 2824
  • [2] Human gamma delta T Cells and Tumor Immunotherapy
    Tanaka, Yoshimasa
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2006, 46 (01) : 11 - 23
  • [3] Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells
    Morandi, Fabio
    Yazdanifar, Mahboubeh
    Cocco, Claudia
    Bertaina, Alice
    Airoldi, Irma
    CELLS, 2020, 9 (08)
  • [4] Targeting gamma delta T cells for cancer immunotherapy: bench to bedside
    Gogoi, Dimpu
    Chiplunkar, Shubhada V.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2013, 138 : 755 - 761
  • [5] T Cell Based Immunotherapy for Cancer: Approaches and Strategies
    Want, Muzamil Y.
    Bashir, Zeenat
    Najar, Rauf A.
    VACCINES, 2023, 11 (04)
  • [6] Genetic engineering of T cells for the immunotherapy of haematological malignancies
    Casucci, M.
    Bondanza, A.
    Falcone, L.
    Provasi, E.
    Magnani, Z.
    Bonini, C.
    TISSUE ANTIGENS, 2012, 79 (01): : 4 - 14
  • [7] Gamma-delta (γδ) T cells: friend or foe in cancer development?
    Zhao, Yijing
    Niu, Chao
    Cui, Jiuwei
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [8] Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy
    Marquez-Medina, Diego
    Salla-Fortuny, Joel
    Salud-Salvia, Antonieta
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (12) : 891 - 895
  • [9] Gamma delta T cells and their immunotherapeutic potential in cancer
    Cieslak, Stephen G.
    Shahbazi, Reza
    BIOMARKER RESEARCH, 2025, 13 (01)
  • [10] Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future
    Saura-Esteller, Jose
    De Jong, Milon
    King, Lisa A.
    Ensing, Erik
    Winograd, Benjamin
    De Gruijl, Tanja D.
    Parren, Paul W. H. I.
    Van Der Vliet, Hans J.
    FRONTIERS IN IMMUNOLOGY, 2022, 13